Table 1. Ingenuity canonical pathways of orthotopic allograft model MSGE.
4T1 | −log (p-value) |
6D1 | −log (p-value) |
Mvt1 | −log (p-value) |
---|---|---|---|---|---|
Granulocyte Adhesion and Diapedesis | 9.25 | Th1 and Th2 Activation Pathway | 17.3 | Antigen Presentation Pathway | 7.19 |
Agranulocyte Adhesion and Diapedesis | 7.16 | Th1 Pathway | 14.9 | Allograft Rejection Signaling | 5.79 |
Th1 and Th2 Activation Pathway | 7.14 | Th2 Pathway | 14.2 | OX40 Signaling Pathway | 4 |
VDR/RXR Activation | 6.89 | iCOS-iCOSL Signaling in T Helper Cells | 11.8 | Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 3.27 |
Th2 Pathway | 6.83 | Altered T Cell and B Cell Signaling in Rheumatoid Arthritis | 11.5 | Cdc42 Signaling | 3.21 |
T Helper Cell Differentiation | 6.2 | Granulocyte Adhesion and Diapedesis | 11.3 | Graft-versus-Host Disease Signaling | 2.97 |
LXR/RXR Activation | 4.97 | Type I Diabetes Mellitus Signaling | 11 | Autoimmune Thyroid Disease Signaling | 2.95 |
Th1 Pathway | 4.97 | CD28 Signaling in T Helper Cells | 10.9 | Protein Ubiquitination Pathway | 2.59 |
iCOS-iCOSL Signaling in T Helper Cells | 4.54 | T Helper Cell Differentiation | 10.8 | Crosstalk between Dendritic Cells and Natural Killer Cells | 2.44 |
Nur77 Signaling in T Lymphocytes | 4.09 | Dendritic Cell Maturation | 10.4 | Systemic Lupus Erythematosus In T Cell Signaling Pathway | 2.35 |